A detailed history of Rock Point Advisors, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Rock Point Advisors, LLC holds 1,433 shares of ABBV stock, worth $257,940. This represents 0.08% of its overall portfolio holdings.

Number of Shares
1,433
Previous 1,433 -0.0%
Holding current value
$257,940
Previous $245,000 15.1%
% of portfolio
0.08%
Previous 0.07%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$159.82 - $182.1 $1,758 - $2,003
-11 Reduced 0.76%
1,433 $260,000
Q3 2023

Nov 09, 2023

BUY
$133.59 - $154.65 $192,903 - $223,314
1,444 New
1,444 $215,000
Q4 2022

Feb 09, 2023

SELL
$138.31 - $165.87 $6,915 - $8,293
-50 Reduced 3.24%
1,494 $241,000
Q3 2022

Nov 10, 2022

BUY
$134.21 - $153.93 $13,421 - $15,393
100 Added 6.93%
1,544 $207,000
Q1 2022

May 10, 2022

BUY
$131.98 - $163.75 $190,579 - $236,455
1,444 New
1,444 $234,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Rock Point Advisors, LLC Portfolio

Follow Rock Point Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Point Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rock Point Advisors, LLC with notifications on news.